Troglitazone induces GLUT4 translocation in L6 myotubes

Diabetes

Volumn 50, Issue 5, 2001, Pages 1093-1101

  Yonemitsu, Shin ^a   Nishimura, Haruo ^a,b   Shintani, Mitsuyo ^a   Inoue, Ryou ^a   Yamamoto, Yuji ^a   Masuzaki, Hiroaki ^a   Ogawa, Yoshihiro ^a   Hosoda, Kiminori ^a   Inoue, Gen ^a   Hayashi, Tatsuya ^a   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SAISEIKAI NAKATSU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ALPHA TOCOPHEROL; CYTOCHALASIN B; DARGLITAZONE; DEOXYGLUCOSE; ETICYCLIDINE; GLUCOSE TRANSPORTER; INSULIN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C; TROGLITAZONE; WORTMANNIN;

ANIMAL CELL; ARTICLE; CHEMICAL STRUCTURE; CHRONOPHARMACOLOGY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; MICROSOME; MYOTUBE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE;

EID: 0035029808     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.5.1093     Document Type: Article

References (53)

1. Insulin resistance: Mechanisms, syndromes, and implications
2. Effect of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes
3. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
4. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability
5. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes
6. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
7. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: No alteration in adipose tissue of obese and NIDDM patients
8. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve upregulation of peroxisome proliferator-activated receptor-gamma
9. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
10. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
11. Troglitazone action is independent of adipose tissue
12. Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents
13. Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb
14. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects
15. Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance
16. Development regulation of the subcellular distribution and glycosylation of GLUT1 and GLUT4 glucose transporters during myogenesis of L6 muscle cells
17. Phosphorylation state of the GLUT4 isoform of the glucose transporter in subfractions of the rat adipose cell: Effects of insulin, adenosine, and isoproterenol
18. Kinetics of GLUT1 and GLUT4 glucose transporters expressed in Xenopus oocytes
19. Substrate specificity and kinetic parameters of GLUT3 in rat cerebellar granule neurons
20. Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues
21. Evidence for 5′AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport
22. Catalytic subunits of the porcine and rat 5′-AMP-activated protein kinase are members of the SNF1 protein kinase family
23. Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay
24. Detection of the GLUT3 facilitative glucose transporter in rat L6 muscle cells: Regulation by cellular differentiation, insulin and insulin-like growth factor-I
25. 5′AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle
26. The AMP-activated protein kinase: Fuel gauge of the mammalian cell?
27. Mammalian AMP-activated protein kinase subfamily
28. The α2 isoform of the 5′AMP-activated protein kinase (AMPK) may mediate contraction-stimulated glucose transport in skeletal muscle
29. Troglitazone has a scavenging effect on reactive oxygen species
30. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone
31. Lilly Lecture 1995: Glucose transport: Pivotal step in insulin action
32. Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine: Fructose-6-phosphate amidotransferase: Decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione
33. Use of bismannose photolabel to elucidate insulin-regulated GLUT4 subcellular trafficking kinetics in rat adipose cells: Evidence that exocytosis is a critical site of hormone action
34. Phosphatidylinositol 3-kinase: Structure and expression of the 110 kd catalytic subunit
35. Morphological effects of wortmannin on the endosomal system and GLUT4-containing compartments in rat adipose cells
36. Glucose transporter recycling in rat adipose cells: Effects of potassium depletion
37. Endocytosis of the glucose transporter GLUT4 is mediated by the GTPase dynamin
38. Expression of a dominant interfering dynamin mutant in 3T3L1 adipocytes inhibits GLUT4 endocytosis without affecting insulin signaling
39. The organization, promoter analysis, and expression of the human PPARγ gene
40. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2
41. Peroxisome proliferator-activated receptor gene expression in human tissues: Effects of obesity, weight loss, and regulation by insulin and glucocoritcoids
42. PPARγ gene expression is elevated in skeletal muscle of obese and type II diabetic subjects
43. Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes
44. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects
45. Rosiglitazone
46. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
47. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice
48. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties
49. Regulation of glucose transport by pioglitazone in cultured muscle cells
50. Possibility of distinct insulin-signaling pathways beyond phosphatidylinositol 3-kinase-mediating glucose transport and lipogenesis
51. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes
52. Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase
53. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells